


**pancreatology, from basics in physiology,  
diagnostics to therapeutic interventions**

**Reiner Wiest, M.D.  
UVCN, Inselspital Bern**


# History and milestones in pancreatic pathophysiology

Sort according to timeline



# History and milestones in pancreatic pathophysiology

Sort according to timeline






# **Anatomy Pancreas**


# Variations in anatomic relations of bile duct and pancreatic duct

Sort by frequency  
present in european population  
10%, 20% and 70%


Which has highest risk of  
Gallstone-pancreatitis ?



Common chanel  
Long terminal seg



common  
terminal segment





Seperate entry of  
CBD and PD into duodenum

**greater risk  
for gallstone  
pancreatitis**

# What is the diagnosis ?

---



43 y female, repetitive pancreatitis unknown origin



**Pancreas divisum**

# What is an incomplete pancreas divisum ?


---






# Variants: Pancreas- Embryology

|   | Time       | Event  |
|---|------------|--|
| 1 | Day 26     | Dorsal Pancreatic duct arises from dorsal side of duodenum               |
| 2 | Day 32     | Ventral Bud arises from base of hepatic diverticulum                     |
| 3 | Day 37     | Contact occurs between the 2 buds. Fusion by end of 6 <sup>th</sup> week |
| 4 | Week 6     | Ventral bud produces the head and uncinate process                       |
| 5 | Week 6     | Ducts Fuse   |
| 6 | Week 6     | Ventral duct and distal portion of dorsal duct form the main duct        |
| 7 | Week 6     | Proximal duct forms the duct of Santorini                                |
| 8 | Month 3    | Acini appear   |
| 9 | Months 3-4 | Islets of Langerhans Appear & become active                              |





# «Meandering Loop Main Pancreatic Duct: Rare anomaly – causing pancreatic hypertension ?



## CASE REPORT

### Meandering Pancreatic Duct as a Cause of Idiopathic Recurrent Pancreatitis

<sup>1</sup>Shyam Sundar, <sup>2</sup>Balaji Purushotham, <sup>3</sup>Rajkumar Rathinasamy, <sup>4</sup>Prabu Kathiresan

## 4 types of meandering main pancreatic duct

Purushotham et al. World J Lap Surg 2018





Fig. 4: Types of MMPD

# **Physiology Pancreas**


# Overview Organs involved in Digestion Secretory Functions

.....



# Islet of Langerhans:

consists of what cells and produce/secret ?



Clusters of endocrine cells as Islet:

75% - B-cells

→ Insulin

20% - A-cells

→ Glucagon

5% - D-cells

→ Somatostatin

Small number

Panc. polypeptide cells

Capillaries draining islet  
cells into portal vein

# What is released/secreted by the pancreas ?

---

## Organic:

### mainly enzymes:

- **$\alpha$ -amylase**: hydrolyses glycogen, starch

-lipolytic enzymes: including

#### lipase:

cholesterol ester hydrolase

phospholipase A2

-**proteolytic** enzymes: including

trypsinogen

chymotrypsin

Pro-Carboxypeptidase A+B

Ribonuclease

Deoxy-ribonuclease

Pro-Elastase

-**Trypsin-Inhibitor**

## Hormones

Insulin

Glucagon

Somatostatin

## Inorganic:

### Mainly Electrolytes

-cations:

Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>, Mg<sup>2+</sup>, Zn<sup>2+</sup>

-anions:

HCO<sub>3</sub><sup>-</sup>, Cl<sup>-</sup> (traces HPO<sub>4</sub><sup>2-</sup>)

**Composition: 99.5% water, 0.05% solids**

# Which stimulus for what pancreatic secretion ?

---

|                                 | Stimulus  | Mediator  | Pancreatic Response   |
|---------------------------------|---|---|---|
| <b><u>Cephalic Phase</u></b>    | Conditioned reflex taste<br>smell, thought of food<br>Unconditioned reflex by<br>taste of food in mouth | Vagus   | little secretion<br>pancreatic enzyme,<br>e.g. PP and HCO <sub>3</sub> <sup>-</sup>   |
| <b><u>Gastric Phase</u></b>     | Distension of stomach<br>Amino acids + Peptides   | Vagus<br>Gastric secretion:<br>Gastrin...                 | little secretion<br>pancreatic enzyme,<br>Low volume high conc.secretion<br>Large secretion with high HCO <sub>3</sub> <sup>-</sup> |
| <b><u>Intestinale Phase</u></b> | Low pH chyme,<br>in duodenum, AA,<br>>C8-FA,MG..<br>Stimulates S-cells.....                             | Vagus<br>Cholecystokinin-<br>Pankreozymin<br>and Secretin | Full pancreatic<br>enzyme response<br>Large secretion with high HCO <sub>3</sub> <sup>-</sup>                                       |



# How to test vagal function: on pancreas ?




**See and smell  
toasted bacon + cheese + bread**

**after 5 minutes  
Chewing half portion  
Spitting each bite  
on napkin**

**Blood samples  
5,10,15 – till 30 min  
after initiation of exposure**


**Analysis for PP**





# Pancreatic Polypeptide.....


---



- **is synthesised and secreted by PP cells  
(also known as gamma cells or F cells) of the pancreatic islets**
- **stimulates migratory motor complex (synergistic with motilin)**
- **affects hepatic glycogen levels and many gastrointestinal secretions (e.g. stimulates gastric acid)**
- **decreases food intake**
- **.....**

# Physiology of pancreatic enzymes: activation

- Synthesis as active enzyme: amylase, lipase, RNAs, DNase
- Proteolytic encyms: synthesis as in-active pro-enzyme (zymogens)



Centro-acinary zymogengranula-secretion: **Trypsinogen**

**ENTERO-KINASE** = membranständige Protease in der Dünndarmmucosa  
aktiviert **Trypsinogen** im Darmlumen







**Trypsin** + Trypsin-Aktivierungskomplex

Autoaktivierung  
von **Trypsin(ogen)**

• **Chymotrypsin-ogen**  
• **Pro-Elastase**  
• **Pro-Carboxypeptidase**  
• **Pro-Phospholipase**

• **Trypsin**

# Acinus/cell: ?



**Synthesis of all main digestive enzymes**  
**Produced as pro-enzymes = stable storage apical part**  
**Protection from autodigestion by:**

*Zymogen-granula = vacuola with membran*  
*Separating trypsinogen from lysosomal enzymes*  
*Ca-concentration cytosolic tightly regulated*  
*low Ca-level protects from premature activation*

# Intra- and Inter-lobular duct cell secretion.....

Secretion by acinar cells is isotonic, resembles plasma


Secretion by intralobular ductal cells has high conc. of  $K^+$  and  $HCO_3^-$

Secretion by extralobular ductal cells is stimulated by secretin, rich in  $HCO_3^-$

## Secretion


water and bikarbonat (1.5-3 L/d), pH 8

for transport of encymes and neutralisation of gastric acid



$HCO_3^-$  directly proportional as rate increases conc increases from 80-120meq/L  
with  $Cl^-$  inversely proportional


# How is pancreatic lipase acting ?



Hydrolases neutral fats to glycerol esters and fatty acids

Is secreted in its final active form but requires colipase in the presence of bile acids thus only in the duodenum (with bile being secreted)

Absorption of resulting FA and MG requires bile salts micelles




**Lipase requires high pH for its activation among food enzymes  
= reason why fat are the hardest of all foods to be digested**





## Total Removal of Pancreas results in ...

---



**Endocrine deficiency of insulin-> Diabetes mellitus**

**Exocrine Insufficiency with development of digestive disturbances:**

✓ **Steatorrhoe**

**Increase in faecal fats: bulky, foul smelling, pale, greasy**

**> 7g Fett/d at 100 fat-intake/day**

✓ **Increase in faecal nitrogen due to incomplete proteolysis**

✓ **Carbohydrate digestion relatively unchanged**

✓ **Loss of about 30% of caloric value of normal diet/ingested food**

# **Diagnostic Work-Up**

**Anamnestic inquiry**


**Genetic testing**

**Autoimmune pancreatitis**

**acute pancreatitis: severity, scores, markers**

**Exocrine pancreatic function**





# What is Nardi-Test when is it positive = SOD ?



**provocation-test with morphine to induce sphincteric spasm  
and  
prostigmine to stimulate pancreatic exocrine secretions**

**Positive as sign for SOD**  
**Elevation of lipase of at least by a factor of four –times normal**  
**coupled with reproduction of the patient's pain**

# Etiology factors linked to acute pancreatitis

---

**G**all stones

**E**thanol

**T**rauma

**S**teroids

**M**umps

**A**utoimmune

**S**corpion venom

**H**yper-lipid, -ca

**E**RCP (5%)

**D**rugs

**GET-SMASHED**

# alcohol and pancreatitis risk

Threshold below which no risk ?

**NO**

Dose-response- relationship ?




Fig. 4. Pooled dose-response risk relationships between average alcohol consumption and acute pancreatitis in women.

Risk for chronic pancreatitis in heavy drinker  
(>80g/day for > 10 years) ?

**About 5%**

# C2 ± Nikotin und Pankreatitis


|                 |  | Alcohol consumption (g/month) |         |                     |
|-----------------|--|-------------------------------|---------|---------------------|
|                 |  | <400                          | ≥400    |                     |
|                 |  | RR† (95% CI)                  | p Value | RR (95% CI)         |
| Smoking status* |  |                               |         |                     |
| Never           |  | 1 (Ref)                       |         |                     |
| Former          |  | 1.30 (0.88 to 1.92)           |         | 0.02                |
| Current         |  | 1.63 (1.12 to 2.37)           |         | <0.01               |
| Pack-years ‡    |  |                               |         |                     |
|                 |  |                               |         | 1 (Ref)             |
|                 |  |                               |         |                     |
|                 |  |                               | 0.20    | 1.97 (0.91 to 4.24) |
|                 |  |                               | 0.21    | 3.96 (1.87 to 8.39) |
| <20             |  | 1.69 (0.99 to 2.90)           | 0.06    | 2.13 (0.84 to 5.40) |
| ≥20             |  | 1.94 (1.18 to 3.19)           | <0.01   | 4.12 (1.98 to 8.60) |

After two decades of smoking cessation risk of non-gallstone-related acute pancreatitis is reduced to a level comparable to that of never smokers

# Natural History of hereditary pancreatitis



Hereditary Pancreatitis: Time to symptom development



Howes et al. Clin Gastroenterol Hepatol. 2004;2(3):252-61



# Risk of pancreatic cancer in HP ?

---

- **standardized incidence ratio 50-87**
- **cumulative risk until age 70: 40%**
  - **low below age 50**
- **needs decades after first clinical presentation**
- **smoking doubles risk –occurrence about 20 years earlier**
  - **diabetes add-on risk factor**

**Number of first and second degree relatives with CA**  
**e.g. two first degree – life time risk about 8 %**



# Genetic testing ?

## When – whom to consider ?

---

### **Before performing molecular analysis- genetic counseling**

**Consider genetic testing for HP when**

- **Family history of idiopathic CP, recurrent pancreatitis or
  - **Childhood pancreatitis (or < 25 years in age with recurrent acute pancreatitis or CP)****
- without explanation after extensive work-up**
- **Relatives with known mutations associated with HP**




# Trypsin(ogen) Regulation

## Trypsin(ogen)

- The **master** enzyme controlling all other digestive enzymes
- Trypsinogen controlled by:
  - **Trypsin(2)**
  - **Calcium(2)**
  - **SPINK1**

Modified from Whitcomb, Hereditary and Childhood Disorders of the Pancreas, Including Cystic Fibrosis. Sleisenger and Fordtran's Gastrointestinal and Liver Diseases, 7th Edition, 2002



# What you know about SPINK1 ?

---

**SPINK1 is an acute phase protein and specific trypsin inhibitor**

**Few SPINK1-mutations directly associated with HP: autosomal-recessive**

**One SPINK1-mutation (c.27delC) inherited autosomal dominant**


**Majority inherited in heterocygous form**

**Phenotypic expression of pancreatitis requires interactions with**


**Other genetic mutations and/or environmental factors**

**= *disease-modifying mutations***

# Mutations in SPINK1 in HP



- **PSTI** Pancreatic Secretory Trypsin-Inhibitor
  - Serin-Protease-Inhibitor, Kazal-Typ 1: SPINK1




In pancreas: inhibits up to 20% of trypsinogen  
e.g. mutation: L14R in 2 european large families:  
rapid intracellular degradation of the mutant protein=  
abolished secretion of SPINK1

# Which genes- when mutated affect risk for HP ?

| Gene                    | Common name                  | Risk Pa-Cancer (CI) |
|-------------------------|------------------------------|---------------------|
| <b>PRSS1</b>            | Hereditary pancreatitis      | SIR 53 (23-105)     |
| <b>STK11/LKB1</b>       | Peutz-Jeghers-Syndrome       | RR 132 (44-261)     |
| <b>CDKN2A</b>           | Fam. Atyp. MMM syndrome      | RR 13-39            |
| <b>MLH1, MSH2, MSH6</b> | Lynch-syndrome               | RR 8 (6-11)         |
| <b>TP53</b>             | Li-Fraumani-Syndrome         | RR 7 (2-19)         |
| <b>BRCA1</b>            | Hereditary breast/ovarian Ca | RR 2 (1.2-4)        |

- **CTRC: Chymotrypsinogen-C**
- **CFTR: cystic fibrosis transmembrane conductance regulator**
  - **Calcium-sensing receptor Gene**
    - **Claudin-2 (CLDN2)**
  - **Carboxypeptidase A1 (CPA1)**

# Genetic Variants Related to Trypsin



AIR = Acute inflammatory response (acute phase protein expression)

- Genes linked to **CP susceptibility** all regulate intra-pancreatic **trypsin** activity.
- Both the acinar cells and duct cells are linked with pancreatitis-causing variations

# PRSS-associated hereditary pancreatitis: progression and CA?

**autosomal dominant**

**penetrance 80%**


**+FA: Pancreatitis attacks from childhood on**

**Progression to chronic pancreatitis**

**forcified by alcohol and nicotin**

**Risk for pancreatic cancer:**

**50j: 10% at age 75: 50%**




**Most frequent mutation (Arg122His)**

**with defect Arg117:**

**Resistent for proteolytic**

**trypsin-degradation**

# PRSS-induced HP is caused by «Super-Trypsin»



Whitcomb 2000


Active trypsin in the pancreas will cause the pancreas to digest itself.

Normally, the pancreas is protected because active trypsin will destroy itself by cutting at R117. This will split the trypsin and inactivate it.

In HP, R117 is mutated to H117. This creates a “super-trypsin” that cannot be inactivated and leads to acute pancreatitis.




# Pathophysiology cystic fibrosis ?




- Mutation CFTR Chlorid-Chanel
- Disturbed secretion of Chlorid-Ions
- and hence, viscous secretion
- Prevalenz 1:2500, heterozygot: 1:25

**CFTR in pancreas = primary molecule  
in bicarbonate conductance**



**WINK1/SPAK activation changes  
CFTR from a **chloride-**  
to a **bicarbonate-**preferring  
channel**



## Two types of autoimmune pancreatitis

|   | Typ I (LPSP)<br>Lymphoplasm. Scleros.<br>Pancreatitis | Typ II (IDCP)<br>Idiopath. ductocentr.<br>Pancreatitis |
|---|---|--|
| <b>Epidemiology</b><br>Age<br>Gender            | Ca. 60% of AIPs<br>M:W = 3:1<br>6th decade            | Ca. 40 % of AIPs<br>M:W = 1:1<br>4./5th decade         |
| <b>Clinic</b><br>Extrapancreatic<br>involvement | Jaundice 75%<br>Acute Pancreatitis 5%<br>YES          | Jaundice 50%<br>Acute Pancreatitis 33%<br>NO           |
| Association with<br>IBD                         | Weak  | Strong CED (v.a. CU)<br>association (10-20%)           |
| <b>Treatment</b><br>Response                    | <b>95-100%</b>  | <b>90-100%</b>   |
| <b>Prognosis</b><br>Relapse Rate                | Up to 60%   | <10%   |

# Serology in AIP ?

---

Liver enzymes, cholestasis markers, lipase

| Typ I  | Typ II  |
|--|---|
| <b>IgG4-Titer increased</b><br><br>increased ANA-, RF,<br>Gamma-Globulinemia | <b>IgG4 normal</b><br><br>almost no alterations |

**IgG4 increased:**  
**> 2-times normal = Level 1**  
**1-2-fach = Level 2**

**NPV 98%**  
**Carcinom: up to 10% increased**  
**(ca. 1-7% also > 2-fach)**  
**The higher the more predictive**  
**> 2-fach: > 90% Spezifisch**

# HISORT means ? Stands for ?

---

**H:** Histology

**I:** Imaging

**S:** Serology

**O:** Other Organ Involvement

**RT:** Response to Treatment

# Histology in AIP- differences in types ?

| Feature                             | Typ I                 | Typ II                |
|-------------------------------------|-----------------------|-----------------------|
| Lymphoplasmatic infiltration        | Yes                   | Yes                   |
| Periductal inflammation             | Yes                   | Yes                   |
| Storiform fibrosis                  | More prominent        | Less                  |
| Obliterative Phlebitis              | <b>Characteristic</b> | Rare                  |
| Granulocyte epithelial lesion (GEL) | Absent                | <b>Characteristic</b> |
| IgG4 staining                       | <b>&gt; 10/HPF</b>    | Rare                  |

**3 of 4 = Level 1**  
**1 or 2 = Level 2**

# How to get best result for histo/cytomorphology ?

---



## Level 1 histology diagnosis AIP:

- 19 G- FNA: 43%\*
- True-Cut-biopsie in pediatric cases: 82% diagnostic yield<sup>o</sup>
- 22 G- FNB: diagnostic sensitivity 62% +

## FNA/B for AIP very heterogenous results ....

- Iwashita T et al. CHG 2012 <sup>o</sup>: Fujii GIE 2013;
- + Kanno et al. CJG 2020 <sup>1</sup>: Kurita et al. GIE 2020


# Imaging in AIP: characteristic features ?

**Sausage-shaped pancreas  
delayed contrast-enhancement in CT  
Level 1 diagnostic for Typ I AIP**

**PS: rim-like capsule  
In only 30-40%  
but very specific**

**Level 2:  
Unclear  
focal/  
mild**


**Level 1:  
= typical  
Pathognom.**





## Imaging in AIP: characteristic features ?


**NMR:**  
diffusely hypointense on T1-weighted images  
and slightly hyperintense on T2-weighted  
images




# Imaging in AIP: characteristic features ?

## Diffusions-MR

Diffusion-coefficient lower in AIP




AIP ( $1.01 \pm 0.11 \times 10^{-3} \text{ mm}^2/\text{s}$ )  
pancreatic cancer ( $1.25 \pm 0.11 \times 10^{-3} \text{ mm}^2/\text{s}$ )  
normal pancreas ( $1.49 \pm 0.16 \times 10^{-3} \text{ mm}^2/\text{s}$ )  
( $P < 0.001$ )



# ERCP for diagnosing AIP ?

main pancreatic duct  
diffus narrowing or long ( $> 1/3$  of PD) or multifocal strictures....



International Consensus Diagnostic Criteria (ICDC: Japan)  
ERP-findings included (not usual in western countries)

# If you do ERCP what to add/perform ?


Pancreatology 15 (2015) 259–264



Contents lists available at ScienceDirect

Pancreatology

journal homepage: [www.elsevier.com/locate/pan](http://www.elsevier.com/locate/pan)



Original article

Comparison of endoscopic retrograde cholangiopancreatography with papillary biopsy and endoscopic ultrasound guided pancreatic biopsy in the diagnosis of autoimmune pancreatitis<sup>†</sup>



Jae Gu Jung<sup>a</sup>, Jong Kyun Lee<sup>b,\*</sup>, Kwang Hyuck Lee<sup>b</sup>, Kyu Taek Lee<sup>b</sup>, Young Sik Woo<sup>b</sup>, Woo Hyun Paik<sup>c</sup>, Do Hyun Park<sup>d</sup>, Sang Soo Lee<sup>d</sup>, Dong Wan Seo<sup>d</sup>, Sung Koo Lee<sup>d</sup>, Myung-Hwan Kim<sup>d,\*\*</sup>


**Papilla biopsy**  
**increased diagnostic sensitivity**  
**from 65%**  
**to 95%**

# Most sensitive test for pancreatic exocrine insufficiency ?

## Secretin-stimulated $\text{HCO}_3^-$ -concentration in duodenal juice (plus EUS-PD)

<80 meq/L  $\text{HCO}_3^-$

Percent Change in Main Pancreatic Duct Diameter  
for Head, Body and Tail  
 $\text{LOG}(100 \cdot (\text{Max} - \text{Min}) / \text{Base})$  vs. Bicarbonate (mEq/L)



Gardner TB et al. Pancreas 2012

EUS-radial measurement PD  
Before and after secretin

| P.Duct in tail | change |
|----------------|--------|
| CP             | 144 %  |
| normal         | 241 %  |
| P-value        | 0.01   |

# Diagnostic exocrine Pancreas-Insufficiency (ePI)

| Test  | Leichte ePI    | Mässige ePI  | Höhergradige ePI | Spezifität    |
|---|----------------|--------------|------------------|---------------|
|   | Sensitivität   | Sensitivität | Sensitivität     |               |
| <b>Elastase-Stuhl</b>                       | <b>54%</b>     | 75%          | <b>95%</b>       | <b>85%</b>    |
| Qual. Stuhlfett                             | 0%             | 0%           | 78%              | 70%           |
| Chymotrypsinakt. Stuhl                      | <50%           | Ca. 60%      | 80-90%           | 80-90%        |
| <b>C13 Atemtest<br/>(gem. Triglyceride)</b> | <b>62-100%</b> | -            | <b>90-100%</b>   | <b>80-90%</b> |

**Pankreas-Elastase im Stuhl: < 200 mikrogramm/g Stuhl  
bei Diarrhoe falsches Ergebnis, nur treffsicher bei höhergradiger Insuffizienz**

# How to monitor creon/lipase-substitution-success ?


## Mixed Triglyceride $^{13}\text{C}$ Atemtest

Gut 1998;43 (suppl 3):S13-S19

Name: Binggeli Jürg  
Geb. Datum: 26.04.1958

## $^{13}\text{C}$ mixed triglyceride breath test

L T Weaver, S Amarri, G R Swart



*C13 labeled fat that is ingested, digested and Absorbed can be detected in exhaled air = reflects lipolysis within the small intestine*

Befund Mixed Triglyceride  $^{13}\text{C}$  Atemtest Fehlfunktion


CPDR innerhalb 240 Minuten > 23% normal  
andernfalls Fehlfunktion (ohne Creon)  
Dieser Test: CPDR = 9.6 %

**Also sensitive in mild forms of ePI  
And only test available to  
monitor under existing  
drug substitution/therapy**







# Model Pathophysiology acute pancreatitis





# What are the most early pro-inflammatory markers in acute pancreatitis ?





# How to differentiate mild- moderate-severe AP ?

In Frühphase  
meist  
Restitutio

## Mild AP

- ▶ No Organfailure
- ▶ No Local- or systemic complications

Mortalität  
fast keine

Entwickeln eine Spätphase  
d.h. nicht < 1 Woche  
Restitutio

## Moderate-severe AP


- ▶ Organfailure, but Resolving < 48 h (= transient) u/o
  - ▶ Lokal- oder systemische Komplikationen  
ohne anhaltendes Organversagen

Mortalität  
erhöht


## Severe AP


- ▶ persistent organfailure >48 h
  - Single organ failure
  - Multiple organ failure

Mortalität  
hoch



## Does serum-lipase help to predict course of AP ?







## Initial predictive value for fatality in acute pancreatitis

|                  | PPV<br>(%) | NPV<br>(%) | Cut-off               |
|------------------|------------|------------|-----------------------|
| <b>IL-6</b>      | <b>91</b>  | <b>82</b>  | <b>&gt; 25 U/ml</b>   |
| PMN-Elastase     | 86         | 79         | > 320µg/l             |
| a2-MG            | 82         | 67         | < 1.5 g/l             |
| <b>CRP</b>       | <b>83</b>  | <b>86</b>  | <b>&gt; 150 mg/dl</b> |
| a1-AT            | 59         | 50         | > 4 g/l               |
| Klinischer Score | 80         | 80         | > 3                   |





# Clinical signs in acute pancreatitis: What is it ?



**Livedo reticularis ?**

**Grey-Turner-sign ?**

**Cullen-sign ?**

**Post-heating-pat ?**


**Naevus ?**



## Acute Abdomen at Pancreatitis




**Grey-Turner-  
sign**



**Cullen-  
sign**





# Skin Signs Acute Pancreatitis

**Grey-Turner      Flanken**

**Cullen**

**Periumbilikal**

Inzidenz

3% ( n = 770)  
(9 GT, 9 C, 5 beides)

**Mortalität**

**37%**

A blue 3D rectangular box with a slight gradient and a shadow effect, containing the text "Therapy/Interventions on Pancreas".

# **Therapy/Interventions on Pancreas**

# Why is it essential if Nardi-Test is positive to differentiate biliary and pancreatic response (lab-work and MRCP)?

---

## Long term effects after sphincterotomy in patients with suspected functional sphincter Oddi disorder: role of Nardi-Test


Vasileios Oikonomou<sup>1</sup>, Martin Maurer<sup>2</sup>, Johannes Heverhagen<sup>2</sup>, Andrew Macpherson<sup>1</sup>, Reiner Wiest<sup>1</sup>

1. Gastroenterology, Clinic for Visceral Surgery and Medicine, University Hospital of Bern,
2. Department of Radiology, University Hospital of Bern.

**Figure 64.5** The complexity of the sphincter of Oddi. (1) Superior choledochal sphincter; (2) inferior choledochal sphincter; (3) ampullary sphincter; (4) pancreatic sphincter.

# 48y alcoholic, jaundice, pruritus – best treatment ?

---



**Fully-covered  
Metal-Stent  
Short 4 cm  
Distal CBD**

# NECROTISING PANCREATITIS – INTENSIVE CARE TREATMENT



# Severe acute pancreatitis: Volume Therapy etc.

## Monitoring vital signs and urine output

Volumensubstitution (25 ml/kg/h)

e.g. Ringer: in 1 l

Early on = essential (> 48 h NO Ben.)

<3.5 L/24 h =  
Letality > 60%  
Gardener Pancreatology 2009

Evtl. even more as bolus (if de-hydrated, hypotonic, tachycardic)  
Controlling success via renal function, urine output or  
creatinin/BUN


**Pro 5mg/dL BUN-increase > Doubling mortality**

Wu et al. Pancreatology 2009

- ✓ Hypocalcemia seeking and correction (ion. calcium)
  - ✓ Glucose-Monitoring
- ✓ **Adequate Pain-management (inkl. Opiates, ggf. PDA)**



# Acute Pancreatitis: Local Complications




[Kozarek, RA. Gastroenterology 1991;100:1362-70 (Case serie)]

[Lau, ST. AmJSurg 2001;181:411-5]




# Acute Pancreatitis: Local Complications



[Kozarek, RA. Gastroenterology 1991;100:1362-70 (Case serie)]

[Lau, ST. AmJSurg 2001;181:411-5]

# Acute Pancreatitis: Local Complications





[Kozarek, RA. Gastroenterology 1991;100:1362-70 (Case serie)]

[Lau, ST. AmJSurg 2001;181:411-5]




# Acute Pancreatitis: Local Complications



[Kozarek, RA. Gastroenterology 1991;100:1362-70 (Case serie)]

[Lau, ST. AmJSurg 2001;181:411-5]

## EUS-interventions



# Infection and Impact on Prognosis of Pseudocyst or WOPN

WOPN (walled-off panc. necrosis)


**Sterile** Nekrose

**Infizierte** Nekrose

Mortalität

ca. 10%

ca. 30%





# Pseudocyst/WOPN: EUS method of choice

- Endosonographie
  - aetiologische Diagnose
  - morphologische Diagnose
  - Therapie/-planung

6666

Name:

m/w:

Alter:

Geburtsdatum:

11/01/2013

14:13:17

Gr:N

Ex:B6

In Stent mobilisierte Nekrose

Doktor:

Kommentar:

66

Name:

m/w:

Alter:

Geburtsdatum:

13/12/2012


13:20:49

Gr:N

Ex:A1

Doktor:

Kommentar:



# best device to remove necrosis endoscopically ....?

---

## Excavator by Ovesco: Innovation Award to





# Removed Sequester, Material...








**Outlook- Future**

# EUS-access portal vein: 19 G FNA



**Circulating tumor cells in pancreatic cancer  
May predict survival**

Waxman I et al. Gastro , Pancreatology 2020



**Metabolic profiling enabling investigations  
On pathophysiology of obesity, diabetes....**

Ryou et al. Am J Physiology 2020




**Portal pressure measurement and HVP-G-  
Analysis .....**

Samarasena et al. GIE 2018

# Utilisation of artificial intelligence for the development of an EUS-convolutional neural netw model trained to enhance the diagnosis of autoimmune pancreatitis

Neil B Marya <sup>1</sup>, Patrick D Powers,<sup>2</sup> Suresh T Chari,<sup>3</sup> Ferga C Gleeson,<sup>1</sup> Cadman L Leggett,<sup>1</sup> Barham K Abu Dayyeh <sup>1</sup>, Vinay Chandrasekhara,<sup>1</sup> Prasad G Iyer <sup>1</sup>, Shounak Majumder <sup>1</sup>, Randall K Pearson,<sup>1</sup> Bret T Petersen,<sup>1</sup> Elizabeth Rajan,<sup>1</sup> Tarek Sawas <sup>1</sup>, Andrew C Storm,<sup>1</sup> Santhi S Vege,<sup>1</sup> Shigao Ch Zaiyang Long,<sup>4</sup> David M Hough,<sup>4</sup> Kristin Mara,<sup>5</sup> Michael J Levy<sup>1</sup>



Article

## MiR-10a in Pancreatic Juice as a Biomarker for Invasive Intraductal Papillary Mucinous Neoplasm by miRNA Sequencing

Natsuhiko Kuratomi <sup>1</sup>, Shinichi Takano <sup>1,\*</sup>, Mitsuharu Fukasawa <sup>1</sup>, Shinya Maekawa <sup>1</sup>, Makoto Kadokura <sup>1</sup>, Hiroko Shindo <sup>1</sup>, Ei Takahashi <sup>1</sup>, Sumio Hirose <sup>1</sup>, Yoshimitsu Fukasawa <sup>1</sup>, Satoshi Kawakami <sup>1</sup>, Hiroshi Hayakawa <sup>1</sup>, Hitomi Takada <sup>1</sup>, Natsuko Nakakuki <sup>1</sup>, Ryoh Kato <sup>1</sup>, Tatsuya Yamaguchi <sup>1</sup>, Yasuhiro Nakayama <sup>1</sup>, Hiromichi Kawaide <sup>2</sup>, Hiroshi Kono <sup>2</sup>, Taisuke Inoue <sup>1</sup>, Tetsuo Kondo <sup>3</sup>, Daisuke Ichikawa <sup>2</sup>

From EUS-Pancreatico-Gastrostomy ?.....think about

Shear Wave Elastography  
First time available on  
Linear EUS

DIA-PANC-Study  
Diagnostic accuracy  
In staging pancreatic cancer

# What should you eat to treat your pancreas well ?



ORIGINAL ARTICLE


## Vegetables, fruit and risk of non-gallstone-related acute pancreatitis: a population-based prospective cohort study

Viktor Oskarsson,<sup>1</sup> Omid Sadr-Azodi,<sup>1,2</sup> Nicola Orsini,<sup>1</sup> Åke Andrén-Sandberg,<sup>2</sup>  
Alicja Wolk<sup>1</sup>

Gut 2017

Keep it simple!

**3. Find  $x$ .**



*Here it is*